Abstract
Cardiovascular disease (CVD) represents one of the most important health problems. One of the main risk factors for CVD death is the high cholesterol levels. Statins have been shown to lower low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular disease, and are currently the first line of treatment for hypercholesterolemia. Atorvastatin is one of the most effective drugs and is part of the blood lipid lowering drug group. This work studies the mechanism of the use of statin family drugs and atorvastatin to determine the clinical requirements for improving the dermatology and the statins.
Highlights
Atorvastatin is a group of drugs that are known to inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase or statins [1]
This study explores the discovery and development of one of those inhibitors called atorvastatin calcium currently marketed under the brand name Lipitor® (Figure 5)
Evidence from extensive studies suggests that statin therapy may reduce the risk of coronary artery disease by 3 to 6 years by 20-40 %
Summary
Statins have been shown to lower low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular disease, and are currently the first line of treatment for hypercholesterolemia. Hamid Yazdani was born in Iran, in 1979 He completed her BSc degree from University of Isfahan Industrial in Chemical engineering. He received his Master's and PhD in Polymer engineering at the Iran Polymer and Petrochemical Institute. He has published more than 20 papers and books He is working as an Assistant Professor at Payame Noor University, Iran. Parisa Shahabi was born in Iran, in 1995 She completed her BSc degree from Semnan University and Payame noor university Tehran East, in applied chemistry.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
